These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10828350)

  • 1. An assessment of the antithymine and antipurine characteristics of MTA (LY231514) in CCRF-CEM cells.
    Chen VJ; Bewley JR; Smith PG; Andis SL; Schultz RM; Iversen PW; Tonkinson JL; Shih C
    Adv Enzyme Regul; 2000; 40():143-54. PubMed ID: 10828350
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate.
    Schultz RM
    Prog Drug Res; 2005; 63():275-300. PubMed ID: 16265884
    [No Abstract]   [Full Text] [Related]  

  • 8. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.
    Walling J
    Invest New Drugs; 2006 Jan; 24(1):37-77. PubMed ID: 16380836
    [No Abstract]   [Full Text] [Related]  

  • 12. [Folic acid antagonists pemetrexed].
    Heinzl S
    Med Monatsschr Pharm; 2004 Jul; 27(7):220-2. PubMed ID: 15296355
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular, biochemical, and cellular pharmacology of pemetrexed.
    Goldman ID; Zhao R
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
    Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
    Simon M; Blatter J; Granzow C
    Anticancer Res; 2007; 27(2):769-73. PubMed ID: 17465201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
    Bodmer N; Walters DK; Fuchs B
    Pediatr Blood Cancer; 2008 Apr; 50(4):905-8. PubMed ID: 17534933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998.
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578
    [No Abstract]   [Full Text] [Related]  

  • 18. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
    Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
    Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamyl hydrolase and the multitargeted antifolate LY231514.
    Rhee MS; Ryan TJ; Galivan J
    Cancer Chemother Pharmacol; 1999; 44(5):427-32. PubMed ID: 10501918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.